Strongbridge Biopharma Plc (SBBP)

1.99
NASDAQ : Health Technology
Prev Close 2.01
Day Low/High 1.95 / 2.02
52 Wk Low/High 1.93 / 6.52
Avg Volume 173.90K
Exchange NASDAQ
Shares Outstanding 54.19M
Market Cap 108.91M
EPS 0.70
P/E Ratio 3.87
Div & Yield N.A. (N.A)

Latest News

Strongbridge Biopharma Plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published In The Lancet Diabetes & Endocrinology

Strongbridge Biopharma Plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published In The Lancet Diabetes & Endocrinology

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities and Characteristic Signs and Symptoms of Cushing's Syndrome ~ ~ RECORLEV Was Generally...

Strongbridge Biopharma Announces Key Leadership Appointments To Support Next Stage Of Growth

Strongbridge Biopharma Announces Key Leadership Appointments To Support Next Stage Of Growth

~ Richard S. Kollender Appointed to Chief Operating Officer ~ ~ Robert Lutz Promoted to Chief Financial Officer ~ ~ David Gill Appointed to Board of Directors ~ DUBLIN, Ireland and TREVOSE, Pa.

Strongbridge Biopharma Plc Reports Second Quarter 2019 Financial Results And Provides Corporate Update

Strongbridge Biopharma Plc Reports Second Quarter 2019 Financial Results And Provides Corporate Update

~ KEVEYIS ® (dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~ ~ Company on Track to Meet Full-Year 2019 KEVEYIS ® Revenue Guidance of $18 to $20 Million ~ ~ Enrollment in Phase 3 LOGICS Study for RECORLEV™ (levoketoconazole) Progressing...

Strongbridge Biopharma Plc To Host Second Quarter 2019 Financial Results Conference Call On July 31, 2019

Strongbridge Biopharma Plc To Host Second Quarter 2019 Financial Results Conference Call On July 31, 2019

DUBLIN, Ireland and TREVOSE, Pa., July 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with...

Strongbridge Biopharma Plc Announces New Employment Inducement Awards

Strongbridge Biopharma Plc Announces New Employment Inducement Awards

DUBLIN, Ireland and TREVOSE, Pa., July 19, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKJ, CETV, CNHI, NEWT, PLYA Downgrades: ACY, BID, DXPE, HRI, IEC, JVA, LONE, MHH, MHO, SBBP, SMTX, UTSI, YRCW Initiations: VCTR Read on to get TheStreet Quant Ratings' detailed report:

Dealing With Biotech Stocks That Face Setbacks

Dealing With Biotech Stocks That Face Setbacks

Knowing when to continue to fish or cut bait is something that develops over time in this space.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Strongbridge Biopharma (SBBP) Shares Cross Above 200 DMA

Strongbridge Biopharma (SBBP) Shares Cross Above 200 DMA

In trading on Thursday, shares of Strongbridge Biopharma plc crossed above their 200 day moving average of $5.08, changing hands as high as $5.16 per share. Strongbridge Biopharma plc shares are currently trading up about 2.7% on the day.

SBBP Makes Bullish Cross Above Critical Moving Average

SBBP Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of Strongbridge Biopharma plc crossed above their 200 day moving average of $5.29, changing hands as high as $5.30 per share. Strongbridge Biopharma plc shares are currently trading up about 7.4% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BTG, DISCA, DISCB, DISCK, FRPT, IPGP, JBT, KOS, MSI, OR, SBBP, SRE, TLRA Downgrades: BIMI, EXTN, NLS, SENEA, SSRM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARRS, RLGT, SCS Downgrades: ATAX, GHM, GRNQ, LAD, RLH Initiations: SBBP Read on to get TheStreet Quant Ratings' detailed report:

RSI Alert: Strongbridge Biopharma (SBBP) Now Oversold

RSI Alert: Strongbridge Biopharma (SBBP) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Strongbridge Biopharma Becomes Oversold (SBBP)

Strongbridge Biopharma Becomes Oversold (SBBP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of August 17th Options Trading For Strongbridge Biopharma (SBBP)

First Week Of August 17th Options Trading For Strongbridge Biopharma (SBBP)

Investors in Strongbridge Biopharma plc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SBBP options chain for the new August 17th contracts and identified the following call contract of particular interest.

Strongbridge Biopharma Breaks Above 200-Day Moving Average - Bullish For SBBP

Strongbridge Biopharma Breaks Above 200-Day Moving Average - Bullish For SBBP

In trading on Friday, shares of Strongbridge Biopharma plc crossed above their 200 day moving average of $7.02, changing hands as high as $7.10 per share. Strongbridge Biopharma plc shares are currently trading up about 6.2% on the day.

Strongbridge Biopharma Is Now Oversold (SBBP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Strongbridge Biopharma Announces Issuance Of Patent For RECORLEV™ (levoketoconazole) For The Treatment Of Cushing's Syndrome

Strongbridge Biopharma Announces Issuance Of Patent For RECORLEV™ (levoketoconazole) For The Treatment Of Cushing's Syndrome

~ Intellectual Property Strengthened with Second Method of Use Patent for RECORLEV ~

Short Interest Increases 93% For SBBP

Short Interest Increases 93% For SBBP

The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 453,809 share increase in total short interest for Strongbridge Biopharma plc , to 942,374, an increase of 92.89% since 01/31/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D+ (Sell)